In hormone receptor-negative, HER2-positive breast cancer, achieving a pathologic complete response (pCR) after neoadjuvant therapy is strongly associated with improved survival outcomes, including higher overall survival and event-free survival rates. The gene discussed is ERBB2; the disease is breast carcinoma.